AOD-9604 in Wagrain — Fat Loss Peptide Research Guide
AOD-9604 research guide for Wagrain. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers trying to source AOD-9604 in Wagrain rapidly learn that local retail options are essentially nonexistent. This matters because AOD-9604 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor determines everything about the product. What consistently distinguishes top AOD-9604 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. The sections below cover what Wagrain researchers need to know about purchasing, testing, and working with AOD-9604 for scientific research use.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Wagrain comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
The first step for any Wagrain researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — organic rankings are no guide to actual AOD-9604 quality. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. For Wagrain researchers evaluating new suppliers: a small initial order to verify quality before committing to research quantities is standard practice in the community. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to approximately one month when stored at 2-8°C.
Order AOD-9604 — ships to Wagrain
COA-verified · International tracking · Research grade
AOD-9604 is available for research use only and is not approved for human consumption by the FDA or comparable health authorities — all information here is educational. Lyophilised AOD-9604 should be frozen at −20°C as soon as it arrives; do not freeze and thaw reconstituted AOD-9604 multiple times by preparing small aliquots before storage. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger dangerous immune responses at trace quantities, and no cost saving makes omitting this acceptable. The research literature on AOD-9604 should be read critically before beginning any research — study methodologies, dosing, and endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
